Zebrafish data supports new drug candidate moving into human clinical trials
Data Form Part of a Successful Safety and Toxicity Filing to the UK's Regulatory Agency MHRA
Summit Corporation plc announced that, for the first time, data generated by its zebrafish technology platform about the safety and toxicity of potential drug candidates has formed part of a successful submission to the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"). This submission has permitted Summit's client, an unnamed UK biotechnology company, to advance its candidate into Phase I human clinical trials.
Summit has built a capability in testing potential drug compounds using zebrafish. This capability is valuable to drug development companies as it rapidly provides important whole organism data about the safety and toxicity of drug-like molecules and is predictive of effects that might be seen in humans. This technology has the potential to accelerate the discovery process and reduce overall costs relating to drug candidates that might otherwise fail as a result of safety or toxicity issues in later stages of development.
Other news from the department research and development
